Clinical trial
DUTCH Weight Control in Atrial Fibrillation Study, a Multi-center, Double-blind, Randomized, Parallel Group, Placebo-controlled Trial
Name
U1111-1275-9989
Description
Quantify the effect of an innovative weight loss management on rhythm control.
Trial arms
Trial start
2024-05-01
Estimated PCD
2026-05-01
Trial end
2027-05-01
Status
Not yet recruiting
Phase
Early phase I
Treatment
Semaglutide 3.2 MG/ML
Intervention arm receives semaglutide in addition to combined lifestyle intervention
Arms:
Intervention
Placebo
Control arm receives placebo in addition to combined lifestyle intervention
Arms:
Placebo
Size
280
Primary endpoint
The primary efficacy clinical endpoint of the trial is assessed at 12 months by a 7 point scale. Only the worst clinical outcome will be retained as the primary efficacy outcome
At 1 year follow-up
Eligibility criteria
Inclusion Criteria:
* Symptomatic, first detected (at maximum 6 months prior to enrollment) persistent AF -
* Age ≥ 18
* Obesity, as defined as:
* BMI ≥ 30 kg/m2, or
* BMI ≥27 kg/m2 with the presence of at least one weight related comorbidity (treated or untreated, e.g. hypertension, dyslipidaemia, obstructive sleep apnea, cardiovascular disease)
* Scheduled ECV
* Written informed consent
Exclusion Criteria:
* Permanent AF
* Secondary AF, i.e. due to thyrotoxicosis, infection (e.g. pneumonia) or post-(cardiothoracic) surgery
* Current or previous treatment with amiodaron
* HbA1c ≥ 48 mmol/L, \<3 months prior to randomization
* History of diabetes mellitus type 1 or 2
* Prior bariatric surgery
* Use of other anti-obesity medication, \<3 months prior to enrollment
* Contra-indication for, or prior use of a GLP1-receptor agonist
* History of chronic pancreatitis or acute pancreatitis \<6 months
* Acute coronary syndrome \<6 months
* Severe (grade III) valvular disease
* eGFR \<30 mL/min/1.73m2
* Heart failure NYHA class III-IV
* Participation in another investigational drug or device study in the past 30 days (registry enrollment is allowed)
* Any condition or therapy, which would make the participant unsuitable for the study (e.g. vulnerable, non-compliance) or life-expectancy \<12 months, as judged by the treating physician.
* Female who is pregnant, breastfeeding, intends to become pregnant, or is of child-bearing potential and not using a highly effective contraceptive method.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 280, 'type': 'ESTIMATED'}}
Updated at
2024-01-08
1 organization
1 product
1 drug
3 indications
Organization
Rijnstate HospitalProduct
SemaglutideIndication
Atrial FibrillationIndication
ObesityIndication
Unintentional Weight LossDrug
Varlilumab